Ra Pharmaceuticals (RARX) reports Q4 loss per share of 47c, announces significant progress on its first XR formulation of zilucoplan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Ra Pharmaceuticals (RARX) reports Q4 loss per share of 47c, announces significant progress on its first XR formulation of zilucoplan

Ra Pharma (RARX) PT Raised to $44 at Raymond James

March 8, 2019 7:32 AM EST

Raymond James analyst Steven Seedhouse raised the price target on Ra Pharma (NASDAQ: RARX) to $44.00 (from $39.00) while maintaining a Strong Buy rating.

... More